We have established strong and lasting relationships with our clients. Here are some things they had to say about us.
"We have been working with Venn Life Sciences for several years on two compounds requiring sophisticated formulation development work. Their deep knowledge and expertise in formulation development enabled us to initiate clinical trials of both programs. Through the collaboration with Venn, we were also able to access to the outstanding features of other services, including CMC, Non-Clinical and Early Clinical consultancy/operational services to achieve the goal. They are talented and committed individuals with great expertise in the scientific and regulatory landscape, and always willing to support us to overcome a number of challenges faced on the projects. I now consider them as a part of our clinical development team”
Akinori Arimura, PhD
Director of Clinical Development at Carna Biosciences, Inc.
“Want to send a thanks to my friends at Venn Life Sciences. After I reached out to the Linked community asking for help to a European regulatory hurdle, they gave their time and found the solution allowing our study in a rare disease to progress. Very grateful.”
"We have been delighted with the work produced by the Venn Life Sciences team to date. We have been working with them closely since the inception of Poolbeg Pharma and their team has been instrumental in guiding our clinical and pre-clinical programs. We look forward to further collaborations with Venn on future projects.”
“Working with Venn has been a great experience. The Venn team is collaborative, responsive and flexible and produce work to a very high standard. They have generously accommodated a shifting timeline in our drug development programme due to unexpected events. I highly recommend working with Venn Life Sciences.”
"The Drug development plan that was created with Venn was a critical success factor for obtaining funding from investors. I am also pleased to see that the plan that was developed 7 years ago remains spot on in the current clinical stage of VarmX."
“We truly appreciate the strong and dedicated CMC and CMC-Regulatory Affairs collaboration with Venn Life Sciences. Over the past 7 years, their support has extended beyond these areas to include non-clinical and clinical topics. This excellent collaboration has been instrumental in the successful submission of our dossier to the FDA.”
